Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study
Authors' conclusion
Our study highlights the sustained effectiveness of MiniMed 780G among youth with T1D. Findings suggest that even children and adolescents with low therapeutic engagement may benefit from SmartGuard technology.
Study context
- Population
- Children and adolescents with T1D starting SmartGuard technology (MiniMed 780G), June 2020–June 2022
- Participants
- 368 children
- Exposure
- MiniMed 780G use at 1 year vs baseline
- Outcome
- Glucose metrics (TIR) and predictors of achieving glycaemic outcomes
- Follow-up
- 12 months
Methodological detailsmulticentre, longitudinal, real-world
- Multicentre
- Longitudinal
- Real-world
Main finding
As reported in the abstract
TIR · 1 year
P < 0.001
Observational data: associations, not effects.
Further findings
Mean HbA1c over study vs previous year · lower over study duration
P < 0.001
Glucose metrics after 15 days of automatic mode
- All glucose metrics improved vs baseline
- P < 0.001
- Time below range
- P = 0.113
- Coefficient of variation
- P = 0.330
Time in tight range (70-140 mg/dL) and glycemia risk index
- Time in tight range (70-140 mg/dL)
- 51.1%
- Glycemia risk index
- 27.6
Predictors of higher time in range (TIR)
- Reduced number of automatic correction boluses
- P < 0.001
- Fewer SmartGuard exits
- P = 0.021
- Longer time in automatic mode
- P = 0.030
TIR in baseline HbA1c >8% subgroup
- TIR improved from baseline to follow-up
- from 54.3% to 72.3%
Original publication
Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study. Diabetes Care. Published 16 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →